Breaking News

Bionano Genomics Announces the Appointment of Stephanie Hoyle as VP Corporate Marketing and Alex Helm as VP Strategic Product Marketing

Bionano Genomics Announces the Appointment of Stephanie Hoyle as VP Corporate Marketing and Alex Helm as VP Strategic Product Marketing

SAN DIEGO, Nov. 04, 2021 (World NEWSWIRE) — Bionano Genomics, Inc. (BNGO), developer of the Saphyr® method that works by using optical genome mapping (OGM) for the detection and assessment of structural variants (SVs), nowadays declared that two former Illumina executives, Stephanie Hoyle and Alex Helm, have joined the Corporation as vice presidents of Corporate Marketing and Strategic Product or service Promoting, respectively. Jointly, they bring 22 many years of experience in the genomics room and 36 yrs of knowledge in internet marketing.

At Bionano, Stephanie will oversee global advertising and manufacturer tactic for the Business. Throughout her tenure at Illumina, she worked in comparable positions and was instrumental in producing the model and advertising method for the Reproductive and Genetic Overall health Company Device, and most not long ago, was the world-wide head of Model Packages, top the company rebrand for the enterprise device. Soon after leaving Illumina, Stephanie founded the Hoyle Promoting Team. She worked with many daily life sciences businesses on manufacturer and internet marketing method, such as BioLegend, ChromaCode, CodexDNA, Fortis Lifetime Sciences, Rady’s Children’s Institute for Genomic Medication and Verogen.

Alex will be liable for acquiring the extensive-time period, world merchandise roadmap and portfolio system for Bionano’s set of solutions and assistance answers to impact the Company’s yearly strategic organizing process. Previously, he was director of Regional Advertising for the Americas at Illumina and responsible for clinical segments like oncology, genetic condition and infectious sickness tests and reproductive health. As the world direct for Illumina’s Reproductive and Genetic Well being Small business Unit, Alex oversaw a crucial solution start for the IVD-marked VeriSeq NIPT Resolution, which appreciably broadened entry to safer prenatal screening for families all over the earth.

“I am thrilled that Stephanie and Alex have joined our crew to lead our manufacturer evolution and strategic item internet marketing planning,” explained Erik Holmlin, PhD, CEO of Bionano Genomics. “By offering greater product or service methods for our customers, our aim is to elevate human overall health and in the end create much better outcomes for sufferers.”

About Bionano Genomics

Bionano is a supplier of genome examination methods that can permit researchers and clinicians to reveal answers to challenging inquiries in biology and medicine. The Company’s mission is to transform the way the environment sees the genome by optical genome mapping (OGM) answers, diagnostic solutions and software program. The Firm features OGM answers for applications throughout basic, translational and clinical investigate. By its Lineagen company, the Firm also presents diagnostic testing for sufferers with scientific displays steady with autism spectrum disorder and other neurodevelopmental disabilities. As a result of its BioDiscovery business enterprise, the Business also offers an industry-foremost, platform-agnostic program answer, which integrates subsequent-generation sequencing and microarray data created to provide assessment, visualization, interpretation and reporting of copy amount variants, solitary-nucleotide variants and absence of heterozygosity throughout the genome in one particular consolidated see. For a lot more details, check out, or

Forward-Hunting Statements of Bionano Genomics

This press launch contains ahead-looking statements within just the indicating of the Private Securities Litigation Reform Act of 1995. Words these as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and identical expressions (as nicely as other terms or expressions referencing long run gatherings, ailments or situation) convey uncertainty of long term events or outcomes and are intended to establish these ahead-searching statements. Forward-looking statements include things like statements pertaining to our intentions, beliefs, projections, outlook, analyses or current anticipations regarding, between other issues: the affect of the expansion of our marketing and advertising leadership group, together with our expectations relating to the advancement of Saphyr® and our potential to bolster buyer knowledge globally. Just about every of these forward-on the lookout statements consists of challenges and uncertainties. Genuine success or developments may possibly vary materially from people projected or implied in these ahead-on the lookout statements. Aspects that may well cause these a variance involve the risks and uncertainties related with: the effects of the COVID-19 pandemic on our small business and the world wide financial system general market problems alterations in the aggressive landscape and the introduction of aggressive products our using the services of endeavours could not achieve the expected benefits variations in our strategic and industrial programs our potential to acquire adequate funding to fund our strategic designs and commercialization endeavours the means of health care and exploration establishments to acquire funding to assistance adoption or ongoing use of our systems the loss of crucial users of administration and our business staff and the hazards and uncertainties associated with our organization and economic ailment in basic, including the dangers and uncertainties explained in our filings with the Securities and Exchange Fee, such as, without having limitation, our Once-a-year Report on Form 10-K for the calendar year finished December 31, 2020 and in other filings subsequently manufactured by us with the Securities and Trade Commission. All ahead-on the lookout statements contained in this press launch communicate only as of the date on which they ended up built and are based on management’s assumptions and estimates as of this sort of day. We do not undertake any obligation to publicly update any forward-hunting statements, no matter if as a outcome of the receipt of new details, the occurrence of foreseeable future gatherings or otherwise.

Organization Make contact with:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]

Trader Relations:
Amy Conrad
Juniper Issue
+1 (858) 366-3243
[email protected]

Media Relations:
Michael Sullivan
+1 (503) 799-7520
[email protected]